

PAHO Revolving Fund: Regional Demand Pooling Perspectives

PAHO/WHO Call for EOI Vaccine
Tech Transfer Hub

9 June 2021

PAHO Member States' Resolutions: Reg. Immunization Program & Revolving Fund

1977

CD25.R27 "Establishment of the Expanded Program on Immunization (EPI) and the PAHO Revolving Fund".

2013

CD52R5 "Principles of the PAHO Revolving Fund for Vaccine Procurement and **CD52/15** "Review of the Charge Assessed on the Procurement of Public Health Supplies for Member States".

2014


CD53/23 Report "PAHO Revolving for vaccine procurement: Challenges and Opportunities".

2017

CSP29/16 "Situation update on the challenges of supplying IPV to maintain polio eradication in the Region".



PAHO's TECHNICAL COOPERATION PACKAGE



Source: Andrus, JK., Toscano, CM., Lewis, M., Oliveira, L., et al. 2007, "A model for enhancing evidence-based capacity to make informed policy decisions on the introduction of new vaccines in the Americas: PAHO's ProVac Initiative", Public Health Reports, 122(6): 811-816.

The Revolving Fund forms part of PAHO's comprehensive technical support involving demand planning - procurement dimensions to ensure access to affordable and assured quality vaccines, syringes and cold chain equipment .

Operations guided by:

Benefits and services to Member States

- Immunization technical program
- Established demand planning process
- Economies of scale
- Lowest-single price
- Transformational agenda



How?

- **Pooled procurement** approach – economies of scale
- **Apply tech criteria** to guide supply allocation minimizing risks of shortages; **coordinate** loans of vaccines to countries
- Keep countries **informed** on global vaccine market dynamics
- **Building capacity** in countries on demand planning and financial sustainability
- Monitor **technical eligibility** of vaccines & respond to claims
- **Leveraging** capital fund and credit line for country financing
- **Transform** customer value proposition, key processes, key resources & sustainability/turnover formula

PAHO's Sustainability Model for National Immunization Programs

National Plans: Vaccine Forecasts (PAHO 173)

Revolving Fund Mechanism:
"Facilitating Access" to Vaccines at Affordable Prices

National Financing: Budgets & Legislation

UTILIZATION OF INFORMATION

PRODUCTO	ESTIMADO CANTIDAD	ESTIMADO MONTO	PRODUCT	QUANTITY	AMOUNT
BCG (1+1) (0.1 ml) (10 doses)	1,800,000	\$558,000	BCG (1+1 years) (0.05 ml/20 doses)	25,000	\$4,512
DTPa (10 doses)	2,100,000	\$515,000	OPV (10 doses)	200,000	\$63,000
Poliovirus B (10 doses)	700,000	\$644,000	DTPa (10 doses)	180,000	\$55,717
SIP Leningrad-Zagreb (10 doses)	1,300,000	\$4,712,000	DTPa/HepB+Hib (1 dose)	130,000	\$76,106
SIPa HepB+Hib (10 doses)	2,400,000	\$1,816,500	Hepatitis B Adult (10 doses)	18,000	\$4,798
OPV (5 doses)	2,600,000	\$14,196,000	Hepatitis B Adult (1 dose)	2,000	\$3,171
OPV (10 doses)	2,100,000	\$378,000	Hepatitis B Pediatric (1 dose)	800	\$807
Anti-Rábica Humana Vero (10 doses)	1,800,000	\$1,394,400	Hib (1 dose)	1,500	\$10,933
Rotavirus (7 doses schedule) (1 dose)	1,540,000	\$1,140,000	HPV Quadrivalent (1 dose)	17,000	\$101,115
PCV 10 (1 dose)	2,400,000	\$12,400,000	Influenza (NH) Trivalent (4-9 years) (10 doses)	20,000	\$94,293
Fiebre Amarilla (10 doses)	2,000,000	\$3,400,000	Influenza (NH) Trivalent (6-35 months) (20 doses)	1,500	\$4,961
MMR Quadrivalent (1 dose)	400,000	\$4,600,000	OPV (5 doses)	40,000	\$151,938
MMR (1 dose)	360,000	\$5,040,000	MMR Leningrad-Zagreb (1 dose)	15,000	\$51,995
Influenza (NH) Trivalent (6-35 meses) (20 doses)	2,238,000	\$2,257,140	MMR Leningrad-Zagreb (5 doses)	70,000	\$126,919
Influenza (NH) Trivalent (6-35 años) (10 doses)	3,125,000	\$8,965,750	PCV 13 (1 dose)	8,000	\$128,088
Anti-Rábica Humana (200 IU)	35,000	\$4,416,200	PPD (5 TU) (1.1 ml) (10 tests)	4,000	\$162,887
Ac. Hepatitis B (100 IU)	8,500	\$180,720	PPSV (23 (1 dose)	6,000	\$60,650
Td (10 doses)	1,000,000	\$190,000	Syringe 0.5 CC AD / 25G X 1"	170,000	\$7,536
Varicela OCA (1 dose)	1,500,000	\$29,400,000	Syringe 0.5 CC AD / 25C X 5/8"	170,000	\$9,676
Poliovirus A (10 doses)	750,000	\$6,407,500	Syringe 0.5 CC CONN / 22G X 1 1/2"	250,000	\$16,129
MMR (5 doses)	6,000	\$15,150	Td (10 doses)	28,000	\$6,209
Anti-Rábica (250 IU)	2,000	\$23,580	Yellow Fever (10 doses)	5,000	\$1,950
Poliovirus B (10,000 IU)	100	\$6,961			
Serping 0.5 CC AD / 25G X 3/8"	800,000	\$57,992			
Serping 0.5 CC AD / 22G X 1 1/2"	4,000,000	\$341,140			
Serping 0.5 CC AD / 23G X 1"	15,000,000	\$646,800			
Serping 0.5 CC AD / 25G X 3/8"	6,000,000	\$194,960			
Serping 1 CC CONN / 22G X 1 1/2"	1,000,000	\$76,740			
Serping 1 CC CONN / 23G X 1"	4,000,000	\$188,080			
TOTAL	51,879,788		TOTAL	51,882,061	

Solidarity Equity Transparency Quality Panamericanism **PAHO Revolving Fund** For Access to Vaccines Demand Performance

Year	2021		
Product / Country	Demand	Reconfirmed	Procured
Td (10 doses)	43,327,060	18,918,606	6,363,580
Anguilla	500	500	500
Antigua and Barbuda	2,000	0	0
Argentina	2,200,000	1,100,000	0
Bahamas	4,500	4,500	4,500
Barbados	5,000	5,000	5,000
Belize	25,000	15,000	15,000
Bermuda	300	300	300
Bolivia	1,869,943	500,000	506,880
Brazil	9,000,000	0	0

Database Feeding

Calculation of Capital Needs

Regional demand consolidation by product

ANNUAL DEMAND COLLECTION WITH MEMBER STATES (PAHO-173)

Order Placement Follow-Up

Information for Tenders

Report Generation

Supplier Allocation


EntityCode	Entity	Product_PAHO173	Q1 Demand	Q2 Demand	Q3 Demand	Q4 Demand	Total Original Demand 2021	Q1 Recon.	Q2 Recon.	Q3 Recon.	Q4 Recon.	Total Recon. 2021 (Q1 to Q4)	
ARG	Ministerio de Salud	Td (10 doses)	550,000	550,000	550,000	550,000	2,200,000	550,000	550,000	550,000	550,000	2,200,000	
BOL	Ministerio de Salud	Td (10 doses)	500,000	500,000	400,000	469,943	1,869,943	0	500,000	400,000	0	900,000	
CHL	Ministerio de Salud	Td (10 doses)	0	282,000	0	0	282,000	0	282,000	0	0	282,000	
COL MOH	Ministerio de Salud	Td (10 doses)	0	500,000	0	500,000	1,000,000	0	500,000	0	500,000	1,000,000	
CR CAIA	Caja Costarricense de Seguro Social	Td (10 doses)	400,000	0	400,000	0	800,000	0	0	0	0	0	
DOM	Ministerio de Salud	Td (10 doses)	0	450,000	0	400,000	850,000	0	450,000	200,000	200,000	850,000	
ECU	Ministerio de Salud	Td (10 doses)	402,000	402,000	0	0	1,204,000	402,000	402,000	0	0	1,204,000	
SLV MOH	Ministerio de Salud	Td (10 doses)	278,000	0	0	0	278,000	278,000	0	0	0	278,000	
GTM MOH	Ministerio de Salud	Td (10 doses)	250,000	250,000	200,000	0	700,000	0	200,000	200,000	0	400,000	
HND	Secretaria de Salud	Td (10 doses)	148,250	148,250	148,250	148,250	593,000	148,250	148,250	148,250	148,250	593,000	
MEX	Instituto Mexicano de Seguridad Social	Td (10 doses)	2,362,530	2,988,580	1,906,110	2,307,880	9,465,100	2,362,530	2,988,580	1,906,110	2,307,880	9,465,100	
NIC	Ministerio de Salud	Td (10 doses)	500,000	450,000	0	0	950,000	500,000	450,000	0	0	950,000	
PAN	Ministerio de Salud	Td (10 doses)	0	300,000	200,000	0	500,000	0	300,000	200,000	0	500,000	
PRY	Ministerio de Salud	Td (10 doses)	0	200,000	0	200,000	400,000	0	100,000	0	0	100,000	
PER	Ministerio de Salud	Td (10 doses)	0	0	0	50,000	50,000	0	0	0	0	50,000	
URY	Ministerio de Salud	Td (10 doses)	0	140,000	140,000	0	280,000	0	140,000	0	0	140,000	
VEN	Ministerio de Salud	Td (10 doses)	3,788,176	3,788,176	2,525,451	2,525,451	12,627,254	3,788,176	3,788,176	0	0	7,576,352	
COL FPMAM	Ministerio de Defensa Nacional	Td (10 doses)	45,720	0	0	0	45,720	31,180	0	0	0	31,180	
							TOTAL ORIGINAL 2021	34,115,017				TOTAL RECONFIRMATION 2021	26,591,632

Solidarity Equity Transparency Quality Panamericanism **PAHO Revolving Fund** For Access to Vaccines **Supplier Allocation 2021**

Product	Q1 Reconfirmation	Q2 Reconfirmation	Q3 Demand	Q4 Demand	Total
MMR Jeryl-Lynn (1 dose)	1,033,467	1,230,986	4,044,585	2,812,531	9,121,569
MMR Leningrad-Zagreb (1 dose)	2,822,093	1,774,450	1,708,646	679,000	6,984,189
Total	3,855,560	3,005,436	5,753,231	3,491,531	16,105,758

Distribution of Countries in the Americas by Influenza Vaccine Formulation Used, 2020

* Globally, the Americas has been the leading region in uptake and delivery of influenza vaccines





Source: Country reports to PAHO, Revolving Fund data for 2019-20 NH influenza season and 2020 SH influenza season. El Salvador also requested NH doses during 2019-20.

RF as a Key Pillar of PAHO's technical cooperation

“One pillar contributing to the success for immunization in the Americas”



1979 -2021
Collecting and leveraging demand
42 years




COVAX deliveries – data as of June 8

LATAM & Caribbean		GLOBAL
31 (~24%)	Countries served	129
17.6 M (~23%)	Volume and Doses	78.1 M

Access is not equal across PAHO RF Member States

Percentage of population covered by existing agreements (May 2021)


- Caribbean and AMC Member States are being left behind
- Access in Brazil and Cuba is heavily dependent on the success of national manufacturers



NOTES

- Overseas territories are not included (the Netherlands and the UK have committed to providing vaccine to cover the full population)
- Does not include doses procured through African Medical Supplies Platform (AMSP)
- Based on supply agreements known to PAHO; there is limited visibility into future donations and bilateral deals
- No adjustment for coverage or wastage; adjusted for doses in schedule

COVID-19 Vaccine demand dynamics are rapidly evolving and will continue to change



Understanding Supply & Market Dynamics


Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process

	Manufacturer	Name of Vaccine	NRA of Record	Platform	EDI accepted	Pre-submission meeting held	Dossier accepted for review*	Status of assessment**	Anticipated decision date***
1.		BNT162b2/COMIRNATY Tozinameran (INN)	EMA	Nucleoside modified mRNA	✓	✓	✓	Finalized	31/12/20
2.		AZD1222	Core – EMA Non-COVAX	Recombinant ChAdOx1 adenoviral vector encoding the Spike protein antigen of the SARS-CoV-2.	✓	✓	✓	In progress Core data Non-Covax. Covax data to be reviewed as EMA post approval change	Earliest by EMA End of January (non-Covax) Additional notes in March/ April for Covax
3.		AZD1222	MFDS KOREA	Recombinant ChAdOx1 adenoviral vector encoding the Spike protein antigen of the SARS-CoV-2.	✓	✓	18 Jan Additional data expected on 29 Jan 2021 (CMC for SK Bio)	Core data (non-covax) in progress (in parallel with EMA); SK Bio data	Earliest 2 nd half Feb 2021

Pipeline Products and Regulatory Pathways



Mapping Tech. Transfer & Regional Opportunities




Monitoring Bilateral Deals



- Continued engagement with the COVAX Facility and global partners



- Monitoring global supply projections and availability



- Facilitating intra-regional dose-sharing



- Identification of optimal product preferences and affordability options for PAHO MS

Demand scenarios for COVID-19 vaccines in 2022 and beyond

- 2022 supply will depend on strategies to address variants (e.g. multivalent vaccines) and signals from global strategy (anticipated demand will impact scale-up plans and potential exit from the market).
- Currently, the WHO SAGE position that there is not yet conclusive evidence on vaccine protection against VOCs
- ***Current unknowns and future dynamics will require interactive demand planning and supply matching approach in 2022 and beyond. PAHO RF role will be critical to ensure demand X supply match.***

Overall Demographic Estimates in Latin American and Caribbean Countries

Total Population	Adult 18+ population	Over 65+	Health Care Workers
650 M	465 M	55 M	23 M

Upcoming: Online COVID-19 Vaccine Demand Mapping Platform

Purpose: to forecast demand for COVID-19 vaccines in Member States for 2021 and 2022

Components of the tool:

- Verify **target population and prioritisation** (*who do you aim to vaccinate?*)
- Verify **supply agreements** (*what is your anticipated vaccine supply?*)
- **Forecast additional vaccine needs** for 2021 and 2022
- Express initial vaccine preferences

Outcome: the information will inform the PAHO strategy for equitable access to COVID-19 vaccines, including scenario building for demand in 2022 and beyond

Supply agreements for covid-19 vaccines

Population Prioritization Target Group **Supply Agreements** Demand Forecast Vaccine Preferences Review

Supply agreements for covid-19 vaccines

PAHO RF has been tracking agreements for covid-19 vaccine supply in Member States. Our information on Covid-19 vaccine supply in your country is summarised below.

1. Modify or add information on existing supply agreements using the "Edit" button.
2. Add other supply agreements using the "Add New Supply Agreements" button

Show 10 entries Search:

Review

Population Prioritization Target Group **Supply Agreements** Demand Forecast Vaccine Preference

Your Representative Information

First name: John **Position:** Asistente
Last name: Doe **Affiliation:** Ministerio de Salud
Mail: jhon.doeMX_Mi@email.com

Population

Country: **Total population:** 20,000,000

Priority Target Groups for Vaccination

Target Group

#	Name	Group Population	Definition	No
1	Essential	2,340,000		

The role of the Revolving Fund in Global Initiatives and Opportunities for Member States to engage in the COVAX facility through PAHO Revolving Fund.



Revolving Fund data infographic



Media contacts


Sebastian Oriel | Daniel Epstein | Nancy Nusser
mediateam@paho.org

Manufacturer	Name of vaccine	MS of interest	Availability	EU EUL/PQ	WHO PQ
Novartis	COVID-19 Vaccine AstraZeneca	EU, Latin America, Caribbean	Available in EU, Latin America, Caribbean	✓	✓
Novartis	COVID-19 Vaccine AstraZeneca	EU, Latin America, Caribbean	Available in EU, Latin America, Caribbean	✓	✓
Novartis	COVID-19 Vaccine AstraZeneca	EU, Latin America, Caribbean	Available in EU, Latin America, Caribbean	✓	✓

https://extranet.who.int/pgweb/sites/default/files/documents/Status_COVID_VAX_20Jan2021_v2.pdf



<https://www.paho.org/en/revolvingfund>



<https://www.paho.org/en/covid-19-vaccines>

